Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models

Biochemical and Biophysical Research Communications

Volumn 433, Issue 4, 2013, Pages 456-462

  Sakamoto, Toshiaki ^a   Ozaki, Kei ichi ^a   Fujio, Kohsuke ^a   Kajikawa, Shu hei ^a   Uesato, Shin ichi ^b   Watanabe, Kazushi ^c   Tanimura, Susumu ^a   Koji, Takehiko ^a   Kohno, Michiaki ^a,c,d  

^a NAGASAKI UNIVERSITY   (Japan)

^b KANSAI UNIVERSITY   (Japan)

^c Proubase Technology Inc   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Combination therapy; ERK pathway; HDAC inhibitor; MEK inhibitor; Synergistic drug interaction

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ENTINOSTAT; MITOGEN ACTIVATED PROTEIN KINASE; SELUMETINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; BENZIMIDAZOLES; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HT29 CELLS; HUMANS; IN SITU NICK-END LABELING; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84876501794     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.009     Document Type: Article

References (29)

1. Oka H., Chatani Y., Hoshino R., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995, 55:4182-4187.
2. Hoshino R., Chatani Y., Yamori T., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.
3. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
4. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
5. Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 2004, 5:875-885.
6. Kohno M., Pouyssegur J. Targeting the ERK pathway in cancer therapy. Ann. Med. 2006, 38:200-211.
7. Kip1. J. Biol. Chem. 2001, 276:2686-2692.
8. Tanimura S., Asato K., Fujishiro S., et al. Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem. Biophys. Res. Commun. 2003, 304:801-806.
9. Tanimura S., Uchiyama A., Watanabe K., et al. Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells. Biochem. Biophys. Res. Commun. 2009, 378:650-655.
10. Yeh T.C., Marsh V., Bernat B.A., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 2007, 13:1576-1583.
11. Rinehart J., Adjei A.A., LoRusso P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
12. Adjei A.A., Cohen R.B., Franklin W., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 2008, 26:2139-2146.
13. Kohno M., Tanimura S., Ozaki K. Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol. Pharm. Bull. 2011, 34:1781-1784.
14. Dent P., Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin. Cancer Res. 2001, 7:775-783.
15. McDaid H.M., Lopez-Barcons L., Grossman A., et al. Enhancement of the therapeutic efficacy of Taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 2005, 62:2854-2860.
16. Haass N.K., Sproesser K., Nguyen T.K., et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induced growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res. 2008, 14:230-239.
17. Watanabe K., Tanimura S., Uchiyama A., et al. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. Clin. Cancer Res. 2010, 16:1170-1178.
18. Ozaki K., Minoda A., Kishikawa F., Kohno M. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. Biochem. Biophys. Res. Commun. 2006, 339:1171-1177.
19. Ozaki K., Kosugi M., Baba N., et al. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem. Biophys. Res. Commun. 2010, 391:1610-1615.
20. Suzuki T., Ando T., Tsuchiya K., et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 1999, 42:3001-3003.
21. Koji T., Hishikawa Y., Ando H., et al. Expression of Fas and Fas ligand in normal and ischemia-reperfusion testes: involvement of the Fas system in the induction of germ cell apoptosis. Biol. Reprod. 2001, 64:946-954.
22. Sos M.L., Koker M., Weir B.A., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009, 69:3256-3261.
23. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol. Int. 1999, 49:91-102.
24. Sebolt-Leopold J.S., Dudley D.H., Herrera R., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999, 5:810-816.
25. Dong C., Davis R.J., Flavell R.A. MAP kinases in the immune response. Annu. Rev. Immunol. 2002, 20:55-72.
26. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
27. Nolan L., Johnson P.W.M., Ganesan A., et al. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. Br. J. Cancer 2008, 99:689-694.
28. CIP1/WAF1. Cancer Res. 2003, 63:3637-3645.
29. Wang X., Martindale J.L., Liu Y., et al. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signaling pathways on cell survival. Biochem. J. 1998, 333:291-300.